A-nor-5α Androstane Oral Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for an effective, stable, and controllable oral dosage form of the A-nor-5α androstane compound to facilitate its therapeutic effects, particularly for anti-cancer and anti-prostatic hyperplasia treatments, as existing formulations lack stability and consistent bioavailability.
Innovation Solution
A novel oral formulation of A-nor-5α androstane compound with a controlled composition of water-soluble adjuvants, minimal water-insoluble adjuvants, and optimized pH stability, using methods like direct powder compression, wet granulation, or dry granulation to ensure high dissolution rates and stability over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic drugs are used, then cancer cells are killed, but normal cells are also damaged causing high toxicity
Solution Approach 1:
The patent segments the therapeutic action by using a novel A-nor-5α androstane compound that specifically targets tumor angiogenesis pathways rather than affecting all rapidly dividing cells. This selective mechanism segments the harmful effect from the therapeutic effect, allowing cancer treatment while sparing normal cells.
Solution Approach 2:
The compound exhibits local quality by demonstrating selective activity specifically at tumor sites through inhibition of tumor angiogenesis. The drug concentrates its effect on tumor blood vessel formation while maintaining low activity in normal tissues, achieving localized therapeutic action with minimal systemic toxicity.
2Ease of operation
If oral formulation is developed for A-nor-5α androstane compound, then therapeutic effect is facilitated, but stability and dissolution control are challenging
Solution Approach 1:
The patent applies parameter changes by optimizing the physical and chemical parameters of the oral formulation, including particle size, crystalline form, and excipient selection. These parameter adjustments enhance the dissolution rate and bioavailability of the compound while maintaining stability during storage and transport.
Solution Approach 2:
The formulation uses composite materials by combining the A-nor-5α androstane compound with specific excipients and adjuvants that improve dissolution and stability. The composite formulation achieves synergistic effects, providing both oral administration convenience and reliable dissolution control.
3Stability of the object's composition
If storage stability is improved under extreme conditions, then formulation reliability is enhanced, but dissolution rate may decrease
Solution Approach 1:
The patent applies preliminary action by pre-optimizing the formulation composition and physical form before storage. The compound is prepared in a specific crystalline form and combined with stabilizing excipients that maintain both stability during storage and dissolution performance after storage, preventing degradation that would otherwise slow dissolution.
Data Source
Figure 1~3
Figure 4~6
AI summary
An oral formulation, and preparation method and use thereof; the oral formulation comprises 1-50 parts by weight of an A-nor-5α-androstane compound, 20-95 parts by weight of a filling agent, 0-20 parts by weight of a disintegrant, 0.1-30 parts by weight of a binder, 0.1-5 parts by weight of a lubricant and 0.1-5 parts by weight of a glidant. The oral formulation has a high stability and a good dissolution performance.